Literature DB >> 14764027

Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum.

M Look1, D Chang, P H Sugarbaker.   

Abstract

The aim of this study was to review the long-term results of cytoreductive surgery in the treatment of advanced primary and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Our goal was to identify clinical factors by which to select patients likely to benefit from a comprehensive management plan. Clinical data of 28 females who underwent surgery were retrieved from a prospective database. Major cytoreductive procedures were possible in 25 patients. Heated intraoperative or early postoperative intraperitoneal chemotherapy was also used where appropriate. The median follow-up after cytoreduction was 26.9 months. The overall median survival after cytoreduction was 45.8 months. The prognostic indicators associated with a statistically significant impact on survival were the prior surgery score (P < 0.001), the completeness of cytoreduction score (CC; P = 0.037), and response to chemotherapy prior to surgery (P = 0.012). Our findings suggest that cytoreductive surgery can be effective when combined with perioperative intraperitoneal chemotherapy. Results can be improved by excluding cases where CC seems unlikely. Extensive prior surgery without the protection of adjunctive intraperitoneal chemotherapy is associated with a poor prognosis. This may be due to disruption of anatomical planes leading to deep abdominal and pelvic dissemination intractable to further treatment.

Entities:  

Mesh:

Year:  2004        PMID: 14764027     DOI: 10.1111/j.1048-891x.2004.14008.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  18 in total

Review 1.  Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Hassan-Alaa-Hammed Al-Shammaa; Yan Li; Yutaka Yonemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

Review 2.  Peritoneal Metastases from Gastrointestinal Cancer.

Authors:  Paul H Sugarbaker
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

Review 3.  Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.

Authors:  Terence C Chua; Greg Robertson; Winston Liauw; Rhonda Farrell; Tristan D Yan; David L Morris
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-23       Impact factor: 4.553

4.  Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review.

Authors:  Paul H Sugarbaker
Journal:  Indian J Surg Oncol       Date:  2019-01-03

5.  Abdominal cocoon.

Authors:  Christian B S Katz; Robert T Diggory; Abdus Samee
Journal:  BMJ Case Rep       Date:  2014-03-28

Review 6.  Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin.

Authors:  F Losa; P Barrios; R Salazar; J Torres-Melero; M Benavides; T Massuti; I Ramos; E Aranda
Journal:  Clin Transl Oncol       Date:  2013-06-06       Impact factor: 3.405

7.  Preoperative Assessment of Cancer Patients with Peritoneal Metastases for Complete Cytoreduction.

Authors:  Paul H Sugarbaker
Journal:  Indian J Surg Oncol       Date:  2016-03-11

8.  Coexistence of tuberculous peritonitis and primary papillary serous carcinoma of the peritoneum: a case report and review of the literature.

Authors:  Xiang-Qian Hou; Hai-Hong Cui; Xing Jin
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

9.  Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses.

Authors:  Chao Zhang; Xiao-ping Li; Heng Cui; Dan-hua Shen; Li-hui Wei
Journal:  J Zhejiang Univ Sci B       Date:  2008-06       Impact factor: 3.066

10.  Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.

Authors:  Emmanuel Guardiola; Delphine Delroeux; Bruno Heyd; Marielle Combe; Veronique Lorgis; Martin Demarchi; Ulrich Stein; Bernard Royer; Bruno Chauffert; Xavier Pivot
Journal:  World J Surg Oncol       Date:  2009-02-09       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.